Novan to Present Successful Clinical Study Results of Lead Product Candidate SB204 for the Treatment of Acne Vulgaris
Abstract Accepted for Presentation at the 23rd World Congress of Dermatology in June 2015
DURHAM, N.C. (January 15, 2015) - Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, announced today that data from a clinical study to assess the safety and pharmacokinetics of SB204 Gel in patients with moderate to severe acne was accepted for presentation at the World Congress of Dermatology to be held in Vancouver on June 8-15, 2015. This global event is held once every five years and is organized by the International League of Dermatological Societies (ILDS).
The Phase 1 study aimed to assess systemic exposure following topical application of SB204 Gel to the chest, back, and face of adults with moderate to severe acne vulgaris. “The results from the successful pharmacokinetic study with SB204 further advance the development of our novel alternative to topical and oral antibiotics,” said Dr. Rico. “I look forward to sharing this data with my international dermatology colleagues at this high impact conference.”
Abstract ID Number 3002037: "Pharmacokinetics of SB204 in subjects with acne vulgaris," J. Rico, E. de Leon, C. Geer, N. Stasko
Presenter: M. Joyce Rico, M.D., Chief Medical Officer, Novan Therapeutics
About Novan, Inc.
Novan Therapeutics is a privately-held, clinical stage biotech company focused on advancing nitric oxide therapies. Nitric oxide, one of the most studied molecules in human physiology, has been shown to exhibit anti-microbial activity and to promote vasodilation, regulate inflammation, stimulate tissue repair, and eradicate cancer cells. Novan’s core technologies solve the previous delivery issues with nitric oxide by stably storing the gaseous species on macromolecules that result in a diverse pipeline of “timed-release” nitric oxide-releasing new chemical entities. The company's proprietary platform technology enables drugable nitric oxide in a variety of dosage forms.
This press release contains forward-looking statements involving risks and uncertainties, both known and unknown, that may cause actual results to differ materially from those indicated. Actual results may differ materially due to a number of factors, including, but not limited to, risks associated with pharmaceutical development, clinical trials that cost more, are less effective and take longer to complete than expected, raw materials and drug supply, changes in regulatory requirements, competition, and financing.
To learn more about Novan Therapeutics, please visit www.novantherapeutics.com.
Julia Brannan, Pascale Communications, LLC, on behalf of Novan Therapeutics